Combination Treatment of Arazyme and Soy Leaf Extract Attenuates Hyperglycemia and Hepatic Steatosis in High-Fat Diet-Fed C57BL/6J Mice
Open Access
Abstract
Arazyme and extracts of soy leaves (ESLs) are used as ingredients for functional foods; however, their combined administration has not been studied. This study assessed the combined effect of Arazyme and ESLs in high-fat-diet (HFD)-induced obese C57BL/6J mice fed 2 mg/kg Arazyme, 50 mg/kg ESLs, or a combination of 2 mg/kg Arazyme and 50 mg/kg ESLs by oral gavage for 13 weeks. Individually, Arazyme and ESLs had no effect on the HFD-induced phenotypes. The combination of Arazyme and ESLs significantly suppressed body weight gain, improved glucose and insulin tolerance, and suppressed hepatic steatosis by reducing lipid synthesis and enhancing lipid utilization gene expression. Furthermore, the combination significantly reduced HFD-induced plasma bile acid reabsorption by suppressing bile acid transporter expression, including the ATP biding cassette subfamily B member 11 (Abcb11), solute carrier family 10 member 1 (Slc10a1), Slc10a2, Slc51a, and Slc51b in the liver and gut. Moreover, the combination of Arazyme and ESLs significantly prevented HFD-induced islet compensation in the pancreas. These results suggest that the incorporation of Arazyme combined with ESLs reduces HFD-induced body weight, hyperglycemia, and hepatic steatosis by regulating liver–gut bile acid circulation in HFD-fed mice. This combination can markedly reduce treatment doses and enhance their therapeutic effects, thereby reducing therapeutic healthcare costs.Keywords
Funding Information
- National Research Foundation of Korea (2016M3A9A5922628)
- Korea Research Institute of Bioscience and Biotechnology (1711134083)
- Jeollanam-do, Republic of Korea (LCM0042011)
This publication has 40 references indexed in Scilit:
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesityNature Communications, 2013
- Metabolic nuclear receptor signaling and the inflammatory acute phase responseTrends in Endocrinology & Metabolism, 2011
- Transgenic expression of cholesterol 7α‐hydroxylase in the liver prevents high‐fat diet–induced obesity and insulin resistance in mice†Hepatology, 2010
- The Akt–SREBP nexus: cell signaling meets lipid metabolismTrends in Endocrinology & Metabolism, 2010
- Hepatoprotective effect of Arazyme on CCl4-induced acute hepatic injury in SMP30 knock-out miceToxicology, 2008
- Are functional foods redefining nutritional requirements?Applied Physiology, Nutrition, and Metabolism, 2008
- Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liverHepatology, 2007
- Characterization of arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture mediumEnzyme and Microbial Technology, 2005
- SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liverJournal of Clinical Investigation, 2002
- SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liverJournal of Clinical Investigation, 2002